Just bumping this in light of the rumour mill swirling wrt the...

Just bumping this in light of the rumour mill swirling wrt the acquisition of Revolution Medicines (RM).


https://www.ft.com/content/93b4e80d-724a-4384-9e39-f6ff9474373a

RM are a clinical drug developer targeting RAS inhibition (i.e. they don't own any approved drugs) just like Mirati were.




6 months ago, RM entered into a funding agreement with the world's largest buyer of pharmaceutical royalties, Royalty Pharma.

https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-enters-2-billion-flexible-funding-agreement

Effectively, the forecast royalty rate that RM has foregone is a meagre 4.29% (consider this dilution).





The $750m balance was available as a debt facility.



Reports are in that they're now in discussions with Merck, only 6 months later, for an astonishing sum - and there's even rumours of other interest.



An unapproved clinical pipeline on track for a US$32B transaction... This is what a 'green circle' exit can look like!